Free Trial

Aadi Bioscience Q4 2022 Earnings Report

Aadi Bioscience logo
$2.79 -0.07 (-2.45%)
As of 02/21/2025 04:00 PM Eastern

Aadi Bioscience EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Aadi Bioscience Revenue Results

Actual Revenue
$5.23 million
Expected Revenue
$4.58 million
Beat/Miss
Beat by +$650.00 thousand
YoY Revenue Growth
N/A

Aadi Bioscience Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Aadi Bioscience Earnings Headlines

3 US Penny Stocks With Market Caps Over $30M To Watch
Aadi Bioscience appoints Dornan as Chief Scientific Officer
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
Aadi Bioscience Leads 3 Promising US Penny Stocks
See More Aadi Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aadi Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aadi Bioscience and other key companies, straight to your email.

About Aadi Bioscience

Aadi Bioscience (NASDAQ:AADI), a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

View Aadi Bioscience Profile

More Earnings Resources from MarketBeat